Publications of H. Eibl
All genres
Journal Article (144)
Journal Article
10 (6), pp. 2168 - 2178 (2004)
Novel temperature-sensitive liposomes with prolonged circulation time. Clinical Cancer Research
Journal Article
116 (Suppl. 4), pp. 24 - 29 (2004)
Leishmaniasis - Oral treatment with hexadecylphosphocholine. Wiener Klinische Wochenschrift
Journal Article
140 (7), pp. 1201 - 1210 (2003)
Alkylglycerol opening of the blood-brain barrier to small and large fluorescence markers in normal and C6 glioma-bearing rats and isolated rat brain capillaries. British Journal of Pharmacology
Journal Article
online, 10.1007/s00430-003-0201-2 (2003)
Miltefosine (Impavido): the first oral treatment against leishmaniasis. Medical Microbiology and Immunology
Journal Article
139 (4), pp. 685 - 694 (2003)
Intracarotid administration of short-chain alkylglycerols for increased delivery of methotrexate to the rat brain. British Journal of Pharmacology
Journal Article
22 (17), pp. 2621 - 2632 (2003)
Intracellular mediators of erucylphosphocholine-induced apoptosis. Oncogene
Journal Article
107 B, pp. 75 - 85 (2003)
FT-IR and NMR studies on the conformational and structural properties of 1,2 Dipalmitoyl-sn-glycero-3-phosphatidyloligoglycerols. Journal of Physical Chemistry
Journal Article
115 (Suppl. 3), pp. 10 - 17 (2003)
Treatment of Acanthamoeba keratitis: standard, problems, and new approaches. Wiener Klinische Wochenschrift
Journal Article
50 (4), pp. 299 - 304 (2002)
Increased delivery of erucylphosphocholine to C6 gliomas by chemical opening of the blood-brain barrier using intracarotid pentylglycerol in rats. Cancer Chemotherapy and Pharmacology
Journal Article
82 (5), pp. 1160 - 1170 (2002)
Erucylphosphocholine-induced apoptosis in glioma cells: involvement of death receptor signalling and caspase activation. Journal of Neurochemistry
Journal Article
1 (10), pp. 877 - 884 (2002)
Combination with an antisense oligonucleotide synergistically improves the antileukemic efficacy of erucylphospho-N,N,N- trimethylpropylammonium in chronic myeloid leukemia cell lines. Molecular Cancer Therapeutics
Journal Article
50 (1), pp. 71 - 79 (2002)
Structure-activity relationships of alkylphosphocholine derivatives: antineoplastic action on brain tumor cell lines in vitro. Cancer Chemotherapy and Pharmacology
Journal Article
46 (3), pp. 695 - 701 (2002)
Cytotoxic activities of alkylphosphocholines against clinical isolates of Acanthamoeba spp. Antimicrobial Agents and Chemotherapy
Journal Article
21 (5), pp. 3389 - 3396 (2001)
Erucylphosphocholine-induced apoptosis in chemoresistant glioblastoma cell lines: Involvement of caspase activation and mitochondrial alterations. Anticancer Research
Journal Article
107, pp. 131 - 139 (2000)
Separation and quantification of alkylphosphocholines by reversed phase high performance liquid chromatography. Chemistry and Physics of Lipids
Journal Article
129, pp. 31 - 32 (1999)
Clinical experiences with cutaneous and visceral leishmaniasis - New strategies for therapy. Schweizerische Medizinische Wochenschrift
Journal Article
44, pp. 484 - 490 (1999)
Erucylphosphocholine: Pharmacokinetics, biodistribution and CNS-accumulation in the rat after intravenous administration. Cancer Chemotherapy and Pharmacology
Journal Article
14, pp. 15 - 22 (1999)
Erucylphosphocholine, a novel antineoplastic either lipid, blocks growth and induces apoptosis in brain tumor cell lines in vitro. International Journal of Oncology
Journal Article
107, pp. 365 - 374 (1999)
BCR-ABL influences the antileukaemic efficacy of alkylphosphocholines. British Journal of Haematology
Journal Article
35 (Suppl. 5), p. 37 (1999)
Requirement of DOPE as ’helper lipid‘ in novel cationic liposomes depends strongly on DNA size and cationic lipid structure. European Journal of Cancer